Journal article
Targeting DNA repair: the genome as a potential biomarker
K Nesic, M Wakefield, O Kondrashova, CL Scott, IA McNeish
Journal of Pathology | WILEY | Published : 2018
DOI: 10.1002/path.5025
Abstract
Genomic instability and mutations are fundamental aspects of human malignancies, leading to progressive accumulation of the hallmarks of cancer. For some time, it has been clear that key mutations may be used as both prognostic and predictive biomarkers, the best-known examples being the presence of germline BRCA1 or BRCA2 mutations, which are not only associated with improved prognosis in ovarian cancer, but are also predictive of response to poly(ADP-ribose) polymerase (PARP) inhibitors. Although biomarkers as specific and powerful as these are rare in human malignancies, next-generation sequencing and improved bioinformatic analyses are revealing mutational signatures, i.e. broader patter..
View full abstractRelated Projects (1)
Grants
Awarded by Rivkin Center for Ovarian Cancer
Funding Acknowledgements
CLS received funding from the National Health and Medical Research Council, Cancer Council Victoria, the Victorian Cancer Agency, and the Australian Government, and is supported by the Stafford Fox Medical Research Foundation. This work was made possible through the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. IAMcN received funding from Cancer Research UK (grant reference A26204), Ovarian Cancer Action, the Rivkin Center for Ovarian Cancer Research, the Wellcome Trust, the Beatson Cancer Charity, and NIHR Imperial BRC.